TITLE

Phytosterols for dyslipidemia

AUTHOR(S)
Malinowski, Jennifer M.; Gehret, Monica M.
PUB. DATE
July 2010
SOURCE
American Journal of Health-System Pharmacy;7/15/2010, Vol. 67 Issue 14, p1165
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose. The efficacy and safety of phytosterols for the management of dyslipidemia are reviewed. Summary. Phytosterols have been evaluated in over 40 clinical trials. The incorporation of 2 g of phytosterols daily into margarine, mayonnaise, orange juice, olive oil, low-fat milk, yogurt, and tablets is associated with significant reductions in lowdensity- lipoprotein (LDL) cholesterol from baseline over 1-12 months in adults with normal or high cholesterol, in children, and in patients with type 2 diabetes mellitus. Phytosterol dosages of 1.6-3 g daily have been shown to reduce LDL cholesterol by 4.1-15% versus placebo within the first month of therapy. One meta-analysis found mean reductions of 10-11%, but results vary. Several placebo-controlled trials found that the addition of phytosterols to statin therapy was associated with reductions of 7-20% in LDL cholesterol for up to 1.5 years. Overall, phytosterols are useful for reducing LDL cholesterol in patients who cannot reach their treatment goal by diet alone or who are taking maximum tolerated doses of statins. These products offer an alternative to statins in patients who cannot take statins or whose statin dosage is restricted because of potential drug interactions or concomitant diseases. Commonly reported adverse effects are primarily gastrointestinal in nature. Conclusion. Phytosterol therapy produces an average 10-11% reduction in LDL cholesterol concentration, but it is unknown whether this effect persists beyond two years. Phytosterol products are well tolerated and have few drug interactions, but their long-term safety has not been established. Current evidence is sufficient to recommend phytosterols for lowering LDL cholesterol in adults.
ACCESSION #
51870151

 

Related Articles

  • LIVALO.  // Monthly Prescribing Reference;Jul2010, Vol. 26 Issue 7, pA.8 

    The article focuses on the drug Livalo from Kowa and Lilly. The drug, a HMG-CoA reductase inhibitor with the active ingredient pitavastatin, is indicated for the treatment of dyslipidemias. The article offers information on the clinical trials of Livalo, along with contraindications,...

  • Gemfibrozil: Once-daily formulation may improve compliance.  // Geriatrics;Dec93, Vol. 48 Issue 12, p58 

    Reports on the findings of a study regarding the use of gemfibrozil for the control of dyslipidemia titled `Once-daily, extended release gemfibrozil in patients with dyslipidemia,' by AM Gotto Jr., WJ Breen, CN Corder et al.

  • Repaglinide and gemfibrozil interaction.  // WHO Drug Information;2004, Vol. 18 Issue 1, p21 

    Reports on an interaction between the short-acting secretagogue repaglinide and lipid-lowering agent gemfibrozil, which is used to treat dyslipidemia. Incidents of hypoglycemic coma in patients using the medications; Changes in repaglinide pharmacokinetics caused by concomitant gemfibrozil...

  • GEMFIBROZIL.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p402 

    The article presents information on antihyperlipidemic drug gemfibrozil, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs and substances.

  • HMG-CoA REDUCTASE INHIBITORS.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2012, p422 

    The article presents information on antihyperlipidemic HMG-CoA reductase inhibitors, including their dosage, indications, adverse reactions, side effects, precautions, and possible interaction with other drugs and substances.

  • COLESEVELAM. GRIFFITH, H. WINTER // Complete Guide to Prescription & Nonprescription Drugs 2012;2010, p272 

    The article presents information on colesevelam, an antihyperlipidemic drug, including its dosage, usage, adverse reactions, side effects, precautions when administering, and possible interaction with other drugs.

  • FIBRATES.  // Complete Guide to Prescription & Nonprescription Drugs 2012;2008, p382 

    The article presents information on fibrates, an antihyperlipidemic agent used for the treatment of lipid disorders. The dosage and usage information is provided. The possible adverse reactions or side effects of the drug, warnings, and precautions are discussed. Possible interaction of the drug...

  • Simvastatin.  // Reactions Weekly;9/6/2008, Issue 1218, p29 

    The article describes the case of a 63-year-old woman who developed rhabdomyolysis following exercise and sauna. The patient had been receiving simvastatin without relevant symptoms for over 6 years to treat her lipid metabolism disorder. The agent was withdrawn following a diagnosis of...

  • Continuing Education Niacin in the treatment of dislipidemia: Insight from Adult Treatment Panel III.  // American Journal of Health-System Pharmacy;7/1/2003 Supplement 2, Vol. 60, pS25 

    Presents a multiple choice-type of quiz about the use of niacin in the treatment of dyslipidemia.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics